Human High Affinity Nerve Growth Factor Receptor, NTRK1 Primacu™ ELI

TRKA is a member of the neurotrophic tyrosine kinase receptor (NTKR) family.

It is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway.

Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed.

Isoform TrkA-I is found in most non-neuronal tissues.

Isoform TrkA-II is primarily expressed in neuronal cells.

TrkA-III is specifically expressed by the pluripotent neural stem and neural crest progenitors.

The presence of NTRK1 leads to cell differentiation and may play a role in specifying sensory neuron subtypes.

Mutations in the TRKA gene have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, mental retardation, and cancer.

It was originally identified as an oncogene as it is commonly mutated in cancers, particularly colon and thyroid carcinomas.

TRKA is required for high-affinity binding to nerve growth factor (NGF), neurotrophin-3 and neurotrophin-4/5 but not brain-derived neurotrophic factor (BDNF).

Known substrates for the Trk receptors are SHC1, PI 3-kinase, and PLC-gamma-1.

NTRK1 has a crucial role in the development and function of the nociceptive reception system as well as the establishment of thermal regulation via sweating.

It also activates ERK1 by either SHC1- or PLC-gamma-1-dependent signaling pathway.

Defects in NTRK1 are a cause of congenital insensitivity to pain with anhidrosis and thyroid papillary carcinoma.

Cancer Immunotherapy Immune Checkpoint Immunotherapy Targeted Therapy